New drug QLC5508 takes on chemo in prostate cancer battle
NCT ID NCT07632690
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial compares an experimental drug, QLC5508, against the standard chemotherapy docetaxel in 700 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. The main goal is to see if QLC5508 delays cancer growth better than docetaxel. Participants will receive either QLC5508 or docetaxel, and the study will track how long the cancer stays under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLC5508 (an experimental drug) and docetaxel (a standard chemotherapy)
What this could lead to
If QLC5508 works better than docetaxel, it could offer a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. QLC5508 may not prove more effective or safer than docetaxel, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••